Clinical Trial Update: A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for LCB84, a TROP2-targeting antibody-drug conjugate, evaluating it as a single agent and in combination with an anti-PD-1 antibody in a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Anti-PD-1 antibody
• LCB84 (LCB84)

Snippet

Sponsor: LigaChem Biosciences, Inc. | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: RECRUITING